Hussein Karim Manji
#147,274
Most Influential Person Across History
Hussein Karim Manji's AcademicInfluence.com Rankings
Download Badge
Philosophy Biology
Hussein Karim Manji's Degrees
- Masters Medicine Harvard University
- PhD Neuroscience Harvard University
Why Is Hussein Karim Manji Influential?
(Suggest an Edit or Addition)Hussein Karim Manji's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. (2006) (2920)
- The cellular neurobiology of depression (2001) (1142)
- Discovering Endophenotypes for Major Depression (2004) (1091)
- New insights into BDNF function in depression and anxiety (2007) (1044)
- Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors (2008) (1020)
- A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. (2010) (868)
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders (2008) (812)
- Enhancement of Hippocampal Neurogenesis by Lithium (2000) (616)
- Preclinical models: status of basic research in depression (2002) (551)
- The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNS (1999) (520)
- Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression (2003) (503)
- The Role of the Extracellular Signal-Regulated Kinase Signaling Pathway in Mood Modulation (2003) (501)
- The Mood‐Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase‐3 (2000) (439)
- Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. (2006) (437)
- Toward Constructing an Endophenotype Strategy for Bipolar Disorders (2006) (416)
- Life Stress, Genes, and Depression: Multiple Pathways Lead to Increased Risk and New Opportunities for Intervention (2004) (408)
- Mood Stabilizer Valproate Promotes ERK Pathway-Dependent Cortical Neuronal Growth and Neurogenesis (2004) (402)
- Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? (2000) (386)
- Impaired mitochondrial function in psychiatric disorders (2012) (382)
- Dynamic regulation of mitochondrial function by glucocorticoids (2009) (376)
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial (2017) (366)
- Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs (2005) (366)
- Neuroplasticity and cellular resilience in mood disorders (2000) (347)
- A double-blind, placebo-controlled study of memantine in the treatment of major depression. (2006) (347)
- Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic–depressive illness (2000) (343)
- Signal transduction pathways. Molecular targets for lithium's actions. (1995) (339)
- The Mood Stabilizer Valproic Acid Activates Mitogen-activated Protein Kinases and Promotes Neurite Growth* (2001) (336)
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. (2016) (334)
- Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. (2001) (331)
- An open-label trial of riluzole in patients with treatment-resistant major depression. (2004) (316)
- Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? (1999) (316)
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. (2019) (308)
- AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. (2004) (307)
- Pramipexole for bipolar II depression: a placebo-controlled proof of concept study (2004) (305)
- The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. (2009) (304)
- Evidence for Selective microRNAs and Their Effectors as Common Long-Term Targets for the Actions of Mood Stabilizers (2009) (291)
- Protein Kinase C Overactivity Impairs Prefrontal Cortical Regulation of Working Memory (2004) (287)
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study (2016) (286)
- A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. (2009) (275)
- Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress (2010) (274)
- Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study (2012) (271)
- Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder (2006) (266)
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. (2018) (265)
- Endophenotypes in bipolar disorder. (2002) (259)
- Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine (2009) (255)
- The FKBP5-Gene in Depression and Treatment Response—an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort (2008) (255)
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. (2019) (250)
- Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers (2004) (244)
- Cellular Plasticity Cascades in the Pathophysiology and Treatment of Bipolar Disorder (2008) (238)
- An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression (2005) (238)
- Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness (1999) (237)
- Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. (2000) (231)
- Elevated Serotonin Transporter Binding in Major Depressive Disorder Assessed Using Positron Emission Tomography and [11C]DASB; Comparison with Bipolar Disorder (2007) (224)
- In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3 (2004) (221)
- How can drug discovery for psychiatric disorders be improved? (2007) (219)
- A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. (2009) (215)
- Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. (2003) (212)
- Signaling: cellular insights into the pathophysiology of bipolar disorder (2000) (210)
- The Anticonvulsants Lamotrigine, Riluzole, and Valproate Differentially Regulate AMPA Receptor Membrane Localization: Relationship to Clinical Effects in Mood Disorders (2007) (209)
- Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. (2007) (208)
- Novel Insights into Lithium’s Mechanism of Action: Neurotrophic and Neuroprotective Effects (2010) (206)
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) (2019) (206)
- Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. (2007) (202)
- Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines (2010) (196)
- Molecular effects of lithium. (2004) (193)
- The neurobiology of the switch process in bipolar disorder: a review. (2010) (190)
- Regulation of Cellular Plasticity Cascades in the Pathophysiology and Treatment of Mood Disorders (2003) (188)
- Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. (2007) (186)
- Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist (2009) (185)
- Serotonin Transporter Binding in Bipolar Disorder Assessed using [11C]DASB and Positron Emission Tomography (2006) (179)
- G proteins: implications for psychiatry. (1992) (178)
- Lithium Decreases Membrane‐Associated Protein Kinase C in Hippocampus: Selectivity for the α Isozyme (1993) (177)
- The Wnt Signaling Pathway in Bipolar Disorder (2002) (177)
- Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. (2013) (177)
- Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response (2009) (176)
- Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. (1999) (171)
- PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers (2002) (167)
- Modulation of Synaptic Plasticity by Antimanic Agents: The Role of AMPA Glutamate Receptor Subunit 1 Synaptic Expression (2004) (165)
- The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders (2009) (165)
- Novel Drugs and Therapeutic Targets for Severe Mood Disorders (2008) (164)
- Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. (2008) (164)
- Chronic Sodium Valproate Selectively Decreases Protein Kinase C α and ε In Vitro (1994) (160)
- Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania (2008) (160)
- The pharmacologic treatment of depression. (1991) (156)
- Mood stabilizers target cellular plasticity and resilience cascades (2005) (156)
- Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study (2013) (152)
- Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. (2004) (150)
- The Female Urine Sniffing Test: A Novel Approach for Assessing Reward-Seeking Behavior in Rodents (2010) (150)
- Habenula Volume in Bipolar Disorder and Major Depressive Disorder: A High-Resolution Magnetic Resonance Imaging Study (2011) (149)
- Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder (2006) (149)
- The underlying neurobiology of bipolar disorder. (2003) (149)
- Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. (2009) (146)
- Mitochondrially Mediated Plasticity in the Pathophysiology and Treatment of Bipolar Disorder (2008) (145)
- Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. (2007) (144)
- Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. (2009) (142)
- Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. (2010) (141)
- Performance on a virtual reality spatial memory navigation task in depressed patients. (2007) (139)
- Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. (2007) (139)
- Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers (2001) (138)
- β-Catenin Overexpression in the Mouse Brain Phenocopies Lithium-Sensitive Behaviors (2007) (138)
- Neurobiology of lithium: an update. (1998) (134)
- Long‐term action of lithium: A role for transcriptional and posttranscriptional factors regulated by protein kinase C (1994) (133)
- Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. (2019) (128)
- Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. (2006) (126)
- Signaling networks in the pathophysiology and treatment of mood disorders. (2002) (121)
- The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers (2006) (121)
- A Naturally Occurring Amino Acid Substitution of the Human Serotonin 5‐HT2A Receptor Influences Amplitude and Timing of Intracellular Calcium Mobilization (1997) (121)
- Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: Further support for the involvement of mitochondrial function in anxiety disorders (2005) (120)
- G protein-coupled receptors in major psychiatric disorders. (2007) (117)
- Potential Mechanisms of Action of Lamotrigine in the Treatment of Bipolar Disorders (2003) (117)
- Protein Kinase C Inhibition by Tamoxifen Antagonizes Manic-Like Behavior in Rats: Implications for the Development of Novel Therapeutics for Bipolar Disorder (2007) (114)
- Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis (2017) (114)
- Bipolar disorder: from genes to behavior pathways. (2009) (114)
- A kinesin signaling complex mediates the ability of GSK-3β to affect mood-associated behaviors (2010) (113)
- Translating genome-wide association findings into new therapeutics for psychiatry (2016) (113)
- Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). (2020) (112)
- The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement (2009) (111)
- The Role of Hippocampal GluR1 and GluR2 Receptors in Manic-Like Behavior (2008) (111)
- The nature of bipolar disorder. (2000) (111)
- Regional Cerebral Glucose Metabolic Abnormalities in Bipolar II Depression (2007) (109)
- Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. (2002) (108)
- Strain Differences in Lithium Attenuation of d-Amphetamine-Induced Hyperlocomotion: A Mouse Model for the Genetics of Clinical Response to Lithium (2007) (107)
- Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. (1999) (107)
- Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients (2009) (105)
- The Role of AMPA receptor modulation in the treatment of neuropsychiatric diseases (2008) (104)
- Sustained Low-Grade Pro-inflammatory State in Unmedicated, Remitted Women with Major Depressive Disorder as Evidenced by Elevated Serum Levels of the Acute Phase Proteins C-reactive Protein and Serum Amyloid A (2007) (104)
- Valproate robustly enhances AP-1 mediated gene expression. (1999) (104)
- Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test (2008) (103)
- Comparative Tolerability Profiles of the Newer versus Older Antidepressants (1994) (103)
- Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets (2011) (102)
- Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication (2010) (102)
- Modulation of Protein Kinase C Isozymes and Substrates by Lithium: The Role of Myo-inositol (1996) (99)
- The effects of lithium on ex vivo cytokine production (2001) (98)
- Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of Mania (2009) (97)
- Mood-stabilizing drugs: mechanisms of action (2012) (96)
- The Anti-Apoptotic, Glucocorticoid Receptor Cochaperone Protein BAG-1 Is a Long-Term Target for the Actions of Mood Stabilizers (2005) (95)
- Abnormal hippocampal functioning and impaired spatial navigation in depressed individuals: evidence from whole-head magnetoencephalography. (2010) (95)
- MicroRNAs in Mental Health: From Biological Underpinnings to Potential Therapies (2009) (93)
- The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. (1991) (93)
- Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. (2000) (92)
- A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. (2008) (91)
- Post-mortem Interval Effects on the Phosphorylation of Signaling Proteins (2003) (91)
- Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) (2020) (91)
- Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. (1995) (91)
- Sympathoneural and adrenomedullary functional effects of &agr;2C-adrenoreceptor gene polymorphism in healthy humans (2005) (89)
- Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. (1999) (89)
- Riluzole in psychiatry: a systematic review of the literature (2008) (88)
- Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. (1999) (87)
- Signal-transducing G proteins and antidepressant Drugs: Evidence for modulation of α subunit gene expression in rat brain (1992) (85)
- Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. (2003) (84)
- Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). (2020) (84)
- Translational research in bipolar disorder: emerging insights from genetically based models (2010) (82)
- Increase in AP-1 Transcription Factor DNA Binding Activity by Valproic Acid (1997) (81)
- The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. (2008) (80)
- Attenuation of Cyclic AMP Production by Carbamazepine (1996) (80)
- BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders (2015) (79)
- Evidence for Involvement of ERK, PI3K, and RSK in Induction of Bcl-2 by Valproate (2009) (78)
- Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. (1994) (78)
- Protein Kinase C Inhibitors (2009) (77)
- Catecholamines in depression: an update. (1994) (76)
- Acute D-serine treatment produces antidepressant-like effects in rodents. (2012) (76)
- The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. (1991) (75)
- Generation and behavioral characterization of β-catenin forebrain-specific conditional knock-out mice (2008) (75)
- Signal Transduction and Genes-to-Behaviors Pathways in Psychiatric Diseases (2003) (74)
- Lithium stimulates gene expression through the AP-1 transcription factor pathway. (1998) (73)
- The Bcl-2 Gene Polymorphism rs956572AA Increases Inositol 1,4,5-Trisphosphate Receptor–Mediated Endoplasmic Reticulum Calcium Release in Subjects with Bipolar Disorder (2011) (73)
- Lithium Activates the c‐Jun NH2‐Terminal Kinases In Vitro and in the CNS In Vivo (1999) (73)
- Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. (1996) (72)
- Lithium Increases Tyrosine Hydroxylase Levels Both In Vivo and In Vitro (1998) (69)
- BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments (2008) (69)
- Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology (2004) (68)
- Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials (2018) (66)
- Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. (2012) (64)
- Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. (2006) (63)
- Glucocorticoid receptors modulate mitochondrial function (2009) (63)
- Lithium: A Molecular Transducer of Mood-Stabilization in the Treatment of Bipolar Disorder (1998) (62)
- Antidepressant-like Effects of Electroconvulsive Seizures Require Adult Neurogenesis in a Neuroendocrine Model of Depression (2015) (62)
- Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. (2003) (62)
- The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. (2003) (61)
- Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile (2012) (61)
- Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions (2010) (61)
- New approaches to modeling bipolar disorder. (2003) (61)
- Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. (2005) (60)
- Reverse translational strategies for developing animal models of bipolar disorder (2009) (60)
- Animal models of suicide-trait-related behaviors. (2009) (59)
- In Search of the Holy Grail for the Treatment of Neurodegenerative Disorders: Has a Simple Cation Been Overlooked? (2007) (59)
- Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness. (1999) (58)
- Structurally Dissimilar Antimanic Agents Modulate Synaptic Plasticity by Regulating AMPA Glutamate Receptor Subunit GluR1 Synaptic Expression (2003) (58)
- High Levels of Gsα in Platelets of Euthymic Patients With Bipolar Affective Disorder (1997) (56)
- DARPP-32: A molecular switch at the nexus of reward pathway plasticity. (2005) (55)
- Novel Drugs and Therapeutic Targets for Severe Mood Disorders (2008) (54)
- Protein Kinase C Inhibitors: Rationale for Use and Potential in the Treatment of Bipolar Disorder (2010) (51)
- Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? (2002) (51)
- The molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry. (2004) (51)
- Down's syndrome and Alzheimer's disease: towards secondary prevention (2012) (51)
- Mood stabilizer psychopharmacology (2002) (51)
- Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. (2001) (49)
- Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study (2000) (49)
- Cellular mechanisms underlying affective resiliency: The role of glucocorticoid receptor- and mitochondrially-mediated plasticity (2009) (48)
- Lithium administration modulates platelet Gi in humans. (1992) (47)
- Neurobiology of bipolar disorder (2008) (47)
- Focus on CaMKII: a molecular switch in the pathophysiology and treatment of mood and anxiety disorders. (2004) (46)
- Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder (2014) (46)
- Effects of Valproic Acid on β-adrenergic Receptors, G-proteins, and Adenylyl Cyclase in Rat C6 Glioma Cells (1996) (45)
- Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. (2003) (45)
- Serotonin Depletion Hampers Survival and Proliferation in Neurospheres Derived from Adult Neural Stem Cells (2010) (44)
- Presynaptic Glutamatergic Dysfunction in Bipolar Disorder (2010) (44)
- Bipolar disorder: candidate drug targets. (2008) (43)
- Effects of electroconvulsive treatment on somatostattn, neuropeptide Y, endothelin, and neurokinin a concentrations in cerebrospinal fluid of depressed patients: A pilot study (1995) (43)
- Roles of p75NTR, Long-Term Depression, and Cholinergic Transmission in Anxiety and Acute Stress Coping (2012) (42)
- The effects of chronic treatment with mood stabilizers on the rat hippocampal post‐synaptic density proteome (2011) (42)
- Arc Regulates Experience-Dependent Persistent Firing Patterns in Frontal Cortex (2014) (42)
- Bipolar disorder: involvement of signaling cascades and AMPA receptor trafficking at synapses. (2004) (40)
- Protein kinase C activity is associated with prefrontal cortical decline in aging (2009) (39)
- Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics (2002) (39)
- Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor (2012) (38)
- Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. (2010) (38)
- Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. (2007) (38)
- Immune targets for therapeutic development in depression: towards precision medicine (2022) (37)
- Differential effect of lithium on cell number in the hippocampus and prefrontal cortex in adult mice: a stereological study (2016) (36)
- Mood disorders: treatment-induced changes in brain neurochemistry and structure. (2002) (35)
- AR-A 014418 , a selective GSK-3 inhibitor , produces antidepressant-like effects in the forced swim test (2004) (35)
- Signal transduction modulation by lithium: cell culture, cerebral microdialysis and human studies. (1991) (34)
- Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/H+ antiporter activity in HL-60 cells. (1990) (34)
- Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. (2008) (34)
- Attention-Deficit and Disruptive Behavior Disorders (2014) (33)
- Getting balance: Drugs for bipolar disorder share target (2002) (32)
- Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience (2011) (31)
- Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. (2011) (30)
- G proteins and beta ARK: a new twist for the coiled coil. (1993) (30)
- Rapid antidepressant effects: moving right along (2013) (29)
- Atrophy of pyramidal neurons and increased stress-induced glutamate levels in CA3 following chronic suppression of adult neurogenesis (2014) (27)
- Neurotransmitters, Receptors, Signal Transduction, and Second Messengers in Psychiatric Disorders. (2004) (26)
- Kinases as drug targets in the treatment of bipolar disorder. (2008) (26)
- Bcl-2 Polymorphism Influences Gray Matter Volume in the Ventral Striatum in Healthy Humans (2009) (25)
- Valproate activates the Notch3/c-FLIP signaling cascade: a strategy to attenuate white matter hyperintensities in bipolar disorder in late life? (2009) (25)
- Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression (2013) (25)
- Empowering 8 Billion Minds: Enabling Better Mental Health for All via the Ethical Adoption of Technologies. (2019) (25)
- Does long-term medication with lithium, clozapine or antidepressants prevent or attenuate dementia in bipolar and depressed patients? (2007) (25)
- Lithium salts in AIDS and AIDS-related dementia. (2002) (25)
- Early intervention in bipolar disorder, part I: clinical and imaging findings (2008) (24)
- Bipolar Medications: Mechanisms of Action (2000) (24)
- Early intervention in bipolar disorder, part II: therapeutics (2008) (23)
- Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. (2007) (23)
- High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder. (1997) (23)
- The effects of prolonged lithium exposure on the immune system of normal control subjects: Serial serum soluble interleukin-2 receptor and antithyroid antibody measurements (1994) (23)
- Psychiatric Disorder (2020) (22)
- Lithium Regulates Total and Synaptic Expression of the AMPA Glutamate Receptor GluR2 in Vitro and in Vivo (2003) (22)
- Neuroimaging in Developmental Clinical Neuroscience (2009) (21)
- Genome‐wide gene expression profiling in GluR1 knockout mice: key role of the calcium signaling pathway in glutamatergically mediated hippocampal transmission (2009) (21)
- Guillain-Barré syndrome associated with COVID-19 infection (2020) (21)
- Estrogen effects on the forced swim test differ in two outbred rat strains (2012) (20)
- A Brain Capital Grand Strategy: toward economic reimagination (2020) (20)
- Neurotrophic Signaling in Mood Disorders (2003) (20)
- Antidepressants, Metabolites, and Apparent Drug Resistance (1990) (20)
- Platelet protein kinase C and brain-derived neurotrophic factor levels in borderline personality disorder patients (2012) (20)
- Down-regulation of PKC alpha by lithium in vitro. (1995) (20)
- Translating depression biomarkers for improved targeted therapies (2015) (20)
- Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants (2012) (20)
- Neuronal Peroxisome Proliferator-Activated Receptor γ Signaling: Regulation by Mood-Stabilizer Valproate (2008) (19)
- The anterior cingulate ERK pathway contributes to regulation of behavioral excitement and hedonic activity. (2009) (19)
- p11 and Gene Therapy for Severe Psychiatric Disorders: A Practical Goal? (2010) (18)
- Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders (2000) (18)
- Assessment of bromocriptine intervention for the treatment of frontal lobe syndrome: a case study. (1992) (18)
- Beyond magic bullets: true innovation in health care (2013) (17)
- Lithium treatment attenuates muscarinic M1 receptor dysfunction (2011) (17)
- Alterations in Cyclic AMP Generation and G Protein Subunits following Transient Ischemia in Gerbil Hippocampus (1995) (17)
- Mania: a rational neurobiology (2008) (16)
- Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study (2019) (15)
- Remote Digital Monitoring for Medical Product Development (2020) (14)
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. (2019) (14)
- Regulation of cellular plasticity and resilience by mood stabilizers: the role of AMPA receptor trafficking (2004) (13)
- Are monoamine metabolites in cerebrospinal fluid worth measuring? (1993) (13)
- Effects of chronic lithium treatment on platelet PKC isozymes in Alzheimer's and elderly control subjects (1993) (13)
- Harnessing digital technology to predict, diagnose, monitor, and develop treatments for brain disorders (2019) (13)
- Acetylcholinesterase inhibition ameliorates deficits in motivational drive (2012) (13)
- Substance dependence. (1998) (13)
- Down-regulation of beta receptors by desipramine in vitro involves PKC/phospholipase A2. (1991) (13)
- Neuroactive steroids, mood stabilizers, and neuroplasticity: alterations following lithium and changes in Bcl-2 knockout mice. (2008) (13)
- S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression (2018) (13)
- G-Protein Level Quantification in Platelets and Leukocytes from Patients with Panic Disorder (1996) (13)
- Rapid Onset of Antidepressant Action: A New Paradigm in the Research and Treatment of Major Depression (2009) (12)
- Cellular plasticity and resilience and the pathophysiology of severe mood disorders (2004) (12)
- Pharmacologic profile of natural products used to treat psychotic illnesses. (1995) (12)
- Guanine nucleotide binding proteins in opioid-dependent patients (1997) (12)
- GSK-3 and neurotrophic signaling: novel targets underlying the pathophysiology and treatment of mood disorders? (2004) (12)
- Bupropion, ECT, and dopaminergic overdrive. (1991) (11)
- Chronic exposure of C6 glioma cells to desipramine desensitizes beta-adrenoceptors, but increases KL/KH ratio. (1991) (11)
- On Redefining the Role of the Immune System in Psychiatric Disease (2006) (11)
- Neurobiology of Severe Mood and Anxiety Disorders (2012) (11)
- Depression, III: treatments. (2003) (11)
- A role for PKC in mediating stress-induced prefrontal cortical structural plasticity and cognitive function (2009) (11)
- Effect of the 5-HT2 antagonist ketanserin on the ECT-induced prolactin release (1989) (11)
- In Vivo Evidence that Nonneuronal β‐Adrenoceptors as Well as Dopamine Receptors Contribute to Cyclic AMP Efflux in Rat Striatum (1994) (10)
- Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders (2002) (10)
- Sleeplessness (1885) (10)
- Behavioral neurobiology of bipolar disorder and its treatment (2011) (10)
- Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. (2021) (9)
- Neurotrophic signaling cascades are major long-term targets for lithium: clinical implications (2004) (9)
- It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
- Serotonin Transporter Binding in Bipolar Disorder Assessed using ( 11 C)DASB and Positron (2006) (8)
- [Possible involvement of protein kinase C in the pathophysiology and treatment of bipolar disorder]. (2004) (8)
- Bipolar disorder: a neurobiological synthesis. (2011) (8)
- Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy (2016) (7)
- Post-mortem Interval Effects on the Phosphorylation of Signaling Proteins (2003) (7)
- Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling. (2006) (7)
- The Antidepressant Effect of β-Adrenoreceptor Subsensitivity: A Brief Review and Clinical Implications* (1987) (7)
- Bag‐1 mediates glucocorticoid receptor trafficking to mitochondria after corticosterone stimulation: Potential role in regulating affective resilience (2020) (6)
- The genetic interacting landscape of 63 candidate genes in Major Depressive Disorder: an explorative study (2014) (6)
- Searching for Rational Anti–N-methyl-D-aspartate Treatment forDepression—Reply (2007) (6)
- S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression (2018) (6)
- Idazoxan down-regulates β-adrenoceptors on C6 glioma cells in vitro (1992) (6)
- Molecular mechanisms of bipolar disorder (2005) (6)
- Partial rodent genetic models for bipolar disorder. (2011) (6)
- Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma (2019) (6)
- MONOAMINERGIC ACTIONS OF ECT (1992) (6)
- 77 CURRENT AND EMERGING TREATMENTS FOR ACUTE MANIA AND LONG-TERM PROPHYLAXIS FOR BIPOLAR DISORDER (2002) (6)
- ASPI: a public–private partnership to develop treatments for autism (2020) (5)
- Emerging novel treatments for severe mood disorders involving cellular plasticity cascades (2006) (5)
- Effects of low dose lithium on hippocampal neuropathology in people at ultra-high risk for psychosis (2007) (5)
- Comment on a Word to the Wise About Intranasal Esketamine. (2019) (5)
- Efficacy and Safety of Intravenous Esketamine in Patients with Treatment-resistant Depression: A Double-blind, Double-randomization, Placebo-controlled Phase 2a Study (2013) (5)
- Chapter 5.7 – Enhancing resilience to stress: the role of signaling cascades (2005) (5)
- Building brain capital (2021) (4)
- Comments to Drs. Bahji, Vazquez, and Zarate. (2021) (4)
- Responsible innovation in technology for mental health care (2020) (4)
- Neuroplasticity: A New Window on Therapeutics in Neuropsychiatric Disease (2008) (4)
- Harnessing the informatics revolution for neuroscience drug R&D (2014) (4)
- ECT and delirium in Parkinson's disease. (1992) (4)
- Chronic Lithium Administration Enhances Noradrenergic Responses to Intravenous Administration of the α2 Antagonist Idazoxan in Healthy Volunteers (2004) (4)
- P.607 Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide: ASPIRE-2 study (2019) (4)
- Intranasal esketamine in treatment resistant depression – a double-blind, randomized, efficacy and dose response study (2016) (3)
- Personality: Neurobehavioural Foundation and Pharmacological Protocols (2014) (3)
- Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al. (2022) (3)
- Potential novel therapeutics for bipolar disorders. (2011) (3)
- Moving from 'diagnose and treat' to 'predict and pre-empt' in neuropsychiatric disorders (2015) (3)
- Harnessing the informatics revolution for neuroscience drug R&D (2014) (3)
- Focus on Bipolar Disorder (2008) (3)
- 74. PERSEVERE: A Study of Esketamine for the Reduction of the Symptoms of Major Depressive Disorder, including Suicidal Ideation, in Subjects Assessed to Be at Imminent Risk for Suicide (2017) (3)
- Neuroplasticity and cellular resilience in bipolar disorder (2002) (2)
- P.323 Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide: aspire-1 study (2019) (2)
- EFFECTS OF LITHIUM ON SIGNAL TRANSDUCTION IN HUMANS (1992) (2)
- Looking Ahead: Electroretinographic Anomalies, Glycogen Synthase Kinase-3, and Biomarkers for Neuropsychiatric Disorders (2014) (2)
- Effects of chronic lithium treatment on signal transduction mechanisms in HL60 cells (1989) (2)
- Pharmacogenomics of Bipolar Disorder (2003) (2)
- Putative Drugs and Targets for Bipolar Disorder (2009) (2)
- Affective State (2020) (2)
- SIGNALING PATHWAYS AND GENE EXPRESSION: MOLECULAR MECHANISMS UNDERLYING MOOD STABILIZATION IN THE BRAIN (1999) (2)
- ECT treatment does not enhance neuroendocrine responses to serotonergic challenge (1992) (2)
- The role of synaptic and cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder (2008) (2)
- Cellular Plasticity Cascades: Genes to Behavior Pathways in the Pathophysiology and Treatment of Bipolar Disorder (2011) (2)
- Genetic variation in HTR 2 A influences serotonin transporter binding potential as measured using PET and [ 11 C ] DASB (2018) (2)
- 105-3 Modulation of brain phosphoinositide signaling by lithium: Relationship to therapeutic response (1997) (2)
- Predictors and outcome of time to presentation among critically ill paediatric patients at Emergency Department of Muhimbili National Hospital, Dar es Salaam, Tanzania (2022) (1)
- P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study (2014) (1)
- MOOD STABILIZERS INCREASE NEUROGENESIS AND NEURITE OUTGROWTH (2000) (1)
- Husseini Manji (2015) (1)
- Cell Membrane and Signal Transduction Pathways—Implications for the Pathophysiology of Bipolar Disorders (2007) (1)
- Attention Deficit Hyperactivity Disorders: Animal Models (2014) (1)
- Molecular and cellular neurobiologic studies identify novel targets for the long-term actions of mood stabilizers (2005) (1)
- Clinical profile and mortality among adult patients presenting with altered mental status to the emergency departments of a tertiary hospital in Tanzania: a descriptive cohort study (2022) (1)
- Carbamazepine increased pregnenolone synthesis blocked by peripheral type benzodiazepine receptor antagonist (1995) (1)
- Update: what’s new in Biological Psychiatry (2001) (1)
- The genetic interacting landscape of 63 candidate genes in Major Depressive Disorder: an explorative study (2014) (1)
- Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A preliminary PET study (2013) (1)
- P.1.08 Associations between plasma BDNF and CCK-4 challenge in healthy subjects (2007) (1)
- The antidepressant effect of beta-adrenoreceptor subsensitivity: a brief review and clinical implications. (1987) (1)
- Serotonin and the postictal prolactin surge (1989) (1)
- Neurodegeneration in Psychiatric Illness (2009) (1)
- POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (2019) (1)
- 196. Mood stabilizers increase neurogenesis and neurite outgrowth (2000) (1)
- The genomics of mood disorders. (2006) (1)
- Neurotransmitters and Receptors in Psychiatric Disorders (2017) (1)
- Bromocriptine in neuroleptic resistance (1987) (1)
- Structural plasticity and neuronal resilience: are these targets for mood stabilizers and antidepressants in the treatment of bipolar disorder? (2002) (1)
- Post hoc analyses of an open-label long-term study of esketamine nasal spray plus an oral antidepressant comparing results in older versus younger adults with treatment-resistant depression (2021) (1)
- S-25-5 Clinical onset of antidepressant action: Implications for new drug development (1996) (1)
- TO PREDICT THE OUTCOME OF TREATMENT WITH ANTIDEPRESSANT MEDICATION (2017) (1)
- 289. Protein kinase C signaling in the treatment of bipolar disorder (1998) (0)
- Predictors and outcome of cardiac arrest in paediatric patients presenting to emergency medicine department of tertiary hospitals in Tanzania (2022) (0)
- Spatial memory performance in patients with mood disorders (2005) (0)
- Immune targets for therapeutic development in depression: towards precision medicine (2022) (0)
- P-18-16 Increased levels of Gαs in platelets of euthymic bipolar affective disorder patients (1996) (0)
- Translational Neuroscience: Mood disorders (2012) (0)
- ASPI: a public–private partnership to develop treatments for autism (2020) (0)
- What is an animal model ? (2005) (0)
- Neuroprotective effects of low-dose lithium in individuals at ultra-high risk of developing psychosis: A case series (2004) (0)
- Contents Vol. 55, 2007 (2007) (0)
- Potential novel treatments for bipolar depression (2009) (0)
- Patterns, Predictors and Outcome of Time to Presentation Among Critically ill Paediatric Patients at Emergency Department of Muhimbili National Hospital, Dar es Salaam, Tanzania (2021) (0)
- Genomic studies identify novel targets for the long term actions of mood stabilizers (2002) (0)
- Translating Genomewide Association Findings into New Therapeutics for Psychiatry 1 (2016) (0)
- Subject Index Vol. 55, 2007 (2007) (0)
- Raising the bar in drug development for depression : antidepressant response in hours instead of weeks (2008) (0)
- Novel Therapeutic Strategies for Bipolar Disorder (2010) (0)
- Publisher Correction: ASPI: a public–private partnership to develop treatments for autism (2020) (0)
- Predictive Validity (2022) (0)
- Residency training on the frontlines of the COVID-19 pandemic - a qualitative study from Tanzania (2021) (0)
- ncreased Anterior Cingulate Cortical Activity in esponse to Fearful Faces: A Neurophysiological iomarker that Predicts Rapid Antidepressant esponse to Ketamine (0)
- The Open Translational Science in Schizophrenia (OPTICS) Project: Janssen clinical trial and NIH data together in an Open-Science collaboration (2016) (0)
- BUPROPION, ECT, AND DOPAMINERGIC OVERDRIVE. REPLY (1991) (0)
- Effects of typical and atypical neuroleptics on plasma and urinary monoamine metabolites (1989) (0)
- Neuroimaging in Developmental Clinical Neuroscience: Foreword (2009) (0)
- Idazoxan down-regulates beta-adrenoceptors on C6 glioma cells in vitro. (1992) (0)
- Recent Advances in Our Understanding of the Neurobiology of Bipolar Disorder (2005) (0)
- Acetylcholinesterase inhibition ameliorates deficits in motivational drive (2012) (0)
- Publisher Correction: ASPI: a public–private partnership to develop treatments for autism (2020) (0)
- Neuroprotective Agents in Mood Disorders: Pathophysiological and Therapeutic Implications (2010) (0)
- Substance Use Disorders in Conflict-Displaced Populations (2020) (0)
- 2009 President's Welcome (2009) (0)
- Reply to Schmidt et al.: The long and the short of BAG1 (2008) (0)
- S.20.04 Lithium responsive behavioural models: a tool for understanding atypical antipsychotic action in bipolar depression and mania (2008) (0)
- Drs. Neumeister and Manji Reply (2005) (0)
- Possible Involvement of Bax Inhibitor 1 (BI-1), A Modulator for Endoplasmic Reticulum (ER) Cellular Stress, in Affective Resilience (2010) (0)
- Jeffrey Scott Nye. (2017) (0)
- ABNORMAL REGULATION OF EXPRESSED GENES IN HUMAN BRAIN DISEASES REVEALED USING cDNA MICROARRAYS (2000) (0)
- Atrophy of pyramidal neurons and increased stress-induced glutamate levels in CA3 following chronic suppression of adult neurogenesis (2013) (0)
- Duke Nukem 3-D: Video games, virtual reality and spatial memory in patients with mood disorders (2005) (0)
- Refractory Depression: Is There a Next Step? (1994) (0)
- Strategies for Gene and Protein Expression Studies in Neuropsychopharmacology and Biological Psychiatry (2001) (0)
- Mood Stabilizers (2021) (0)
- S14 IMPAIRMENTS OF CELLULAR PLASTICITY AND RESILIENCE IN SEVERE MOOD DISORDERS: THERAPEUTIC IMPLICATIONS (2005) (0)
- S.18.02 The molecular and cellular neurobiology of bipolar disorder (2003) (0)
- Direct Targets of Lithium , Valproate , and Carbamazepine : Drugs Used to Treat Bipolar Disorder (2006) (0)
- Molecular Mechanisms Underlying Mood Stabilization in Manic-Depressive Illness: The Phenotype Challenge (2019) (0)
- S.4.01 Molecular drug targets for bipolar disorders (2010) (0)
- P.038 Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from five phase-3 studies (2019) (0)
- S-33-3 Regulation of transmembrane signalling systems by mood stabilizing agents: Therapeutic implications (1996) (0)
- COMBINED MEASURES OF NORADRENERGIC OUTPUT AND RECEPTOR RESPONSIVITY IN DEPRESSION (1992) (0)
- 47. Lithium and VPA increases the function of a novel transcription factor (1998) (0)
- A Prospective, observational cohort study to identify neonates and children at risk of postdischarge mortality in Dar es Salaam, Tanzania and Monrovia, Liberia: the PPDM study protocol (2022) (0)
- Blue-native Gel Electrophoresis Reveals Role of Cardiolipin in Yeast Mitochondrial Supercomplex Assembly and Stability Discovery of Platelet Proteomic Biomarkers in Patients with Bipolar Depression After Acute and Chronic Treatment with Lithium (2006) (0)
- 128. Regulation of AP-1 DNA binding activity by lithium and VPA (1998) (0)
- Lithium as a Mood Lithium as a Mood Stabiliser in the Stabiliser in the Treatment of Bipolar Treatment of Bipolar Disorder Disorder (0)
- Jeffrey Scott Nye (2017) (0)
- G proteins: Molecular targets for gonadal steroids (1994) (0)
- Activities of Daily Living (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Hussein Karim Manji?
Hussein Karim Manji is affiliated with the following schools:
